Cellectar Biosciences, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Cellectar Biosciences, Inc. has filed its 2023 10-K report detailing financial performance, stock-related activities, and key corporate events.</b>

AI Summary

Cellectar Biosciences, Inc. (CLRB) filed a Annual Report (10-K) with the SEC on March 27, 2024. Cellectar Biosciences, Inc. filed its 2023 Form 10-K on March 27, 2024, reporting on its fiscal year ended December 31, 2023. The filing details financial data including retained earnings and additional paid-in capital for fiscal years 2021, 2022, and 2023. It includes information on stock options and contingent non-statutory stock option awards for the periods ending December 31, 2023, and January 31, 2023. The report references fair value adjustments of warrants and costs and expenses related to the fiscal year 2023. Key dates for financial reporting and corporate actions, such as the October 2022 public offering and private placement, are noted.

Why It Matters

For investors and stakeholders tracking Cellectar Biosciences, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Cellectar Biosciences' financial health and operational activities for the fiscal year 2023, crucial for investors assessing the company's current standing and future prospects. The detailed financial data, including equity and expense breakdowns, allows stakeholders to understand the company's capital structure, investment in research and development, and overall financial management.

Risk Assessment

Risk Level: — Cellectar Biosciences, Inc. shows moderate risk based on this filing. The company's financial disclosures, while detailed, do not provide sufficient information on revenue or profitability trends to definitively assess its financial strength or growth trajectory, necessitating further investigation into operational performance.

Analyst Insight

Investors should analyze the detailed financial statements and risk factors within the 10-K to understand Cellectar Biosciences' financial position and strategic direction.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period for the 10-K.)
• 2024-03-27 — Filing Date (Date the 10-K was filed.)

Key Players & Entities

• Cellectar Biosciences, Inc. (company) — Filer of the 10-K report.
• 2023 (date) — Fiscal year end date.
• March 27, 2024 (date) — Filing date of the 10-K.
• December 31, 2023 (date) — Conformed period of report.
• October 2022 (date) — Reference to a public offering and private placement.

FAQ

Industry Context

Cellectar Biosciences operates in the pharmaceutical preparations industry, focusing on the development of novel therapies.

Regulatory Implications

The filing is a standard 10-K annual report required by the SEC for public companies to disclose financial and operational information.

What Investors Should Do

1. Review the detailed financial statements for revenue, net income, and cash flow.
2. Examine the risk factors section for potential challenges and uncertainties.
3. Analyze the executive compensation and stock option details for insights into management incentives.

Key Dates

• 2023-12-31: Fiscal Year End — Reporting period for the 10-K.
• 2024-03-27: Filing Date — Date the 10-K was filed.

Year-Over-Year Comparison

This filing represents the annual 10-K report for the fiscal year ended December 31, 2023, providing updated financial and operational information compared to previous filings.

Key Financial Figures

• $0.00001 — ch registered Common stock, par value $0.00001 CLRB Nasdaq Capital Market Securi
• $2M — omas). This study is partially funded (~$2M) by a National Institutes of Health SBI

Filing Documents

• clrb-20231231x10k.htm (10-K) — 1598KB
• clrb-20231231xex21d1.htm (EX-21.1) — 4KB
• clrb-20231231xex23d1.htm (EX-23.1) — 2KB
• clrb-20231231xex31d1.htm (EX-31.1) — 11KB
• clrb-20231231xex31d2.htm (EX-31.2) — 11KB
• clrb-20231231xex32d1.htm (EX-32.1) — 6KB
• 0001410578-24-000307.txt (&nbsp;) — 6411KB
• clrb-20231231.xsd (EX-101.SCH) — 43KB
• clrb-20231231_cal.xml (EX-101.CAL) — 48KB
• clrb-20231231_def.xml (EX-101.DEF) — 189KB
• clrb-20231231_lab.xml (EX-101.LAB) — 364KB
• clrb-20231231_pre.xml (EX-101.PRE) — 312KB
• clrb-20231231x10k_htm.xml (XML) — 958KB

Forward-Looking Statements

Forward-Looking Statements 2 PART I 4 Item 1.

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 30 Item 1B. Unresolved Staff Comments 54 Item 1C. Cybersecurity 54 Item 2.

Properties

Properties 54 Item 3.

Legal Proceedings

Legal Proceedings 54 Item 4. Mine Safety Disclosures 54 PART II 55 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 55 Item 6. Reserved 56 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 56 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 58 Item 8.

Financial Statements

Financial Statements 59 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 78 Item 9A.

Controls and Procedures

Controls and Procedures 78 Item 9B. Other Information 79 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 79 PART III 79 Item 10. Directors, Executive Officers, and Corporate Governance 79 Item 11.

Executive Compensation

Executive Compensation 80 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 80 Item 13. Certain Relationships and Related Transactions, and Director Independence 80 Item 14. Principal Accounting Fees and Services 80 PART IV 81 Item 15. Exhibits, Financial Statement Schedules 81 Item 16 Summary 82

Signatures

Signatures 83 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This annual report on Form 10-K of Cellectar Biosciences, Inc. (the "Company", "Cellectar", "we", "us", "our") contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act. Examples of our forward-looking statements include: our current views with respect to our business strategy, business plan and research and development activities; the progress of our product development programs, including clinical testing and the timing of commencement and results thereof; our projected operating results, including research and development expenses; our ability to continue development plans for iopofosine I 131 (iopofosine, also known as CLR 131), CLR 1900 series, CLR 2000 series, and CLR 12120; our ability to continue development plans for our Phospholipid Drug Conjugates (PDC); our ability to maintain orphan drug designation in the U.S. for iopofosine as a therapeutic for the treatment of multiple myeloma, neuroblastoma, osteosarcoma, rhabdomyosarcoma, Ewing's sarcoma and lymphoplasmacytic lymphoma, and the expected benefits of orphan drug status; any disruptions at our sole supplier of iopofosine; our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise; our ability to advance our technologies into product candidates; our enhancement and consumption of current resources along with ability to obtain additional funding; our current view regarding general economic and market conditions, including our competitive strengths; the future impacts of the COVID-19 pandemic on our business, employees, operating results, ability to recruit patients for clinical studies, ability to obtain additional funding, product development programs, research and development programs, suppliers and third-party manufacturers; uncertainty and economic instability resulting from conflicts, military

Business

Item 1. Business. Business Overview We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. We believe that our PDC platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments, and we plan to develop PDCs both independently and through research and development collaborations. Our lead PDC therapeutic, iopofosine I 131 (iopofosine) is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. We believe this profile differentiates iopofosine from many traditional on-market treatments and radiotherapeutics. Our CLOVER-WaM Phase 2 pivotal study of iopofosine in patients with relapsed/refractory (r/r) Waldenstrom's macroglobulinemia (WM) has completed, and our Phase 2b studies in r/r multiple myeloma (MM) patients and r/r central nervous system lymphoma (CNSL) are ongoing. The CLOVER-2 Phase 1a study for a variety of pediatric cancers has concluded and a Phase 1b study in pediatric patients with high grade glioma is enrolling. Additionally, a Phase 1 Investigator-initiated study conducted by the University of Wisconsin Madison of iopofosine I 131 in combination with external beam radiation in patients with recurrent head and neck cancer has also completed. As with all clinical trials, adverse events, serious adverse events or fatalities may arise during a clinical trial resulting from medical problems that may not be related to clinical trial treatments. The CLOVER-1 Phase 2 study, conducted in r/r B-cell malignancies, met the primary efficacy endpoints from the Part A

View Full Filing

View this 10-K filing on SEC EDGAR